Cardior Pharmaceuticals

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company founded in 2016, based in Germany. The company specializes in developing RNA-based therapeutics aimed at preventing, repairing, and reversing heart diseases. Their innovative approach involves using distinctive non-coding RNAs to address the root causes of cardiac dysfunctions. With a mission to bring transformative therapeutics and diagnostics to patients globally, Cardior Pharmaceuticals recently received a significant €64.00M Series B investment on August 25, 2021. The investors in this round include BioMed Partners, Coparion, Fund+, Hadean Partners, Sunstone Partners, Inkef, EQT Life Sciences, HTGF | High-Tech Gruenderfonds, and Bristol-Myers Squibb. Notably, as of May 2, 2024, Cardior Pharmaceuticals GmbH became a wholly owned subsidiary of Novo Nordisk Region Europe A/S. With its focus on addressing cardiac diseases, Cardior Pharmaceuticals is poised to make a lasting impact on the treatment of heart-related ailments worldwide.